Skip to main content
SpringerLink
Log in

Clear pharmacokinetic advantages with microemulsion formulation of cyclosporin

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®). Drugs 1995; 50(5): 924–41

    Article  PubMed  CAS  Google Scholar 

  2. Burke JF, Pirsch JD, Ramos E, et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994; 331: 358–63

    Article  PubMed  Google Scholar 

  3. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752–7

    Article  PubMed  CAS  Google Scholar 

  4. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725–38

    Article  PubMed  CAS  Google Scholar 

  5. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994 Oct; 26: 2925–7

    PubMed  CAS  Google Scholar 

  6. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995 Feb 27; 59: 505–511

    PubMed  CAS  Google Scholar 

  7. Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213–6

    Article  PubMed  CAS  Google Scholar 

  8. Frei U, Taesch S, Niese D. Use of Sandimmun Neoral in renal transplant patients. Transplant Proc 1994 Oct; 26: 2928–31 (Study in 2 parts. Pt A)

    PubMed  CAS  Google Scholar 

  9. Neumayer HH, Färber L, Haller P, et al. Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. Nephrol Dial Transplant 1996; 11: 165–172

    Article  PubMed  CAS  Google Scholar 

  10. Pollak R. The Neora™ vs Sandimmune® soft-gelatin capsule randomized multicenter three-month double-blind trial (N-103): tolerability and safety profiles. In: Neoral™: The new Microemulsion Formulation of Cyclosporine, Special Report, May 1995. Cedar Knolls, New Jersey, USA: World Medical Press, 1995: 19–27

    Google Scholar 

  11. Niese D, on behalf of the International Sandimmun Neoral Study Group. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. Transplant Proc 1995 Apr; 27: 1849–56

    PubMed  CAS  Google Scholar 

  12. Levy G, Altraif I, Rezieg M. et al. Cyclosporine Neoral in liver transplant recipients. Transplant Proc 1994 Dec; 26: 3184–7

    PubMed  CAS  Google Scholar 

  13. Svendsen U, Larsen K, Allermand H, et al. Neoral conversion study: shift from Sandimmune classic formulation to Sandimmmune Neoral in heart and lung transplant patients. Transplant Proc 1995 Dec; 27: 3477

    PubMed  CAS  Google Scholar 

  14. Neumayer HH. Cyclosporin as microemulsion — is it a new drug? Nephrol Dial Transplant 1996; 11: 19–20

    Article  PubMed  CAS  Google Scholar 

  15. Keown P, Lawen JG, Landsberg D, et al. Economic analysis of Sandimmune Neoral in Canada in stable renal transplant patients. Transplant Proc 1995 Apr; 27: 1845–8

    PubMed  CAS  Google Scholar 

  16. Tsunoda SM and Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996 Feb; 30(2): 107–40

    Article  PubMed  CAS  Google Scholar 

  17. Friman S, Bäckman L. A new microemulsion formulation of cyclosporin. Pharmacokinetic and clinical features. Clin Pharmacokinet 1996 Mar; 30(3): 181–93

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clear pharmacokinetic advantages with microemulsion formulation of cyclosporin. Drugs Ther. Perspect 7, 6–8 (1996). https://doi.org/10.2165/00042310-199607060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607060-00003

Keywords

Search

Navigation